 |
| 메디톡스. (사진=메디톡스) |
[Alpha Biz=(Chicago) Reporter Paul Lee] Medytox announced on the 7th that it achieved consolidated sales of 221.1 billion won, operating profit of 17.3 billion won, and net profit of 9.6 billion won last year. Sales rose 13 percent from the previous year, the largest sales since the company was founded, but operating profit and net profit fell 63 percent and 74 percent, respectively, from the previous year.
The cost of preparing for the U.S. Food and Drug Administration (FDA) permit and ongoing litigation costs were cited as the main reasons for the decline in profits.
"Some of the ongoing lawsuits will be completed this year and all costs are expected to decrease," the company said. "The recovery of sales cost to the original level by the normal operation of the second plant is also expected to have a positive effect on profits."
Last year's sales were growing overall. Compared to the previous year, overseas sales of botulinum toxin increased by 16% and domestic sales by 26%. Filler sales also increased by 4% overseas and 11% domestically, respectively, from the previous year.
This year, Medytox has set a goal of breaking its sales last year and has been expanding its production by operating its production line as much as possible since the beginning of the year.
Alphabiz Reporter Kim SangJin(hoondork1977@alphabiz.co.kr)
